Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China,
Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China,
Int J Nanomedicine. 2019 Mar 22;14:2029-2053. doi: 10.2147/IJN.S197889. eCollection 2019.
Cancer is a major public health problem, and is now the world's leading cause of death. Traditional Chinese medicine (TCM)-combination therapy is a new treatment approach and a vital therapeutic strategy for cancer, as it exhibits promising antitumor potential. Nano-targeted drug-delivery systems have remarkable advantages and allow the development of TCM-combination therapies by systematically controlling drug release and delivering drugs to solid tumors. In this review, the anticancer activity of TCM compounds is introduced. The combined use of TCM for antitumor treatment is analyzed and summarized. These combination therapies, using a single nanocarrier system, namely codelivery, are analyzed, issues that require attention are determined, and future perspectives are identified. We carried out a systematic review of >280 studies published in PubMed since 1985 (no patents involved), in order to provide a few basic considerations in terms of the design principles and management of targeted nanotechnology-based TCM-combination therapies.
癌症是一个主要的公共卫生问题，现在是世界上主要的死亡原因。中药（TCM）联合治疗是一种新的治疗方法，也是癌症的重要治疗策略，因为它显示出有希望的抗肿瘤潜力。纳米靶向药物传递系统具有显著的优势，可以通过系统控制药物释放和将药物递送到实体瘤来开发 TCM 联合疗法。在这篇综述中，介绍了 TCM 化合物的抗癌活性。分析和总结了 TCM 联合抗肿瘤治疗的应用。对使用单一纳米载体系统（即共递药）的这些联合疗法进行了分析，确定了需要注意的问题，并提出了未来的展望。我们对 1985 年以来（不包括专利）在 PubMed 上发表的>280 项研究进行了系统综述，以便为基于靶向纳米技术的 TCM 联合疗法的设计原则和管理提供一些基本的考虑。
